No Data
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Largest Shareholders Are Private Companies With 46% Ownership, Individual Investors Own 35%
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
BAIYUNSHAN PH (00874.HK): Liu Luan has been nominated as a candidate for the Shareholder representative supervisor.
On December 24, Gelonghui reported that BAIYUNSHAN PH (00874.HK) announced that the Board of Directors received a notification from the company's Board of Supervisors, stating that the chairman of the Board of Supervisors, Cai Ruiyu, resigned from his position as the chairman of the ninth Board of Supervisors and as the shareholder representative supervisor due to work adjustments. On the same day, it was announced that Liu Min was nominated as a candidate for shareholder representative supervisor at the tenth meeting of the ninth Board of Supervisors to be held on December 24, 2024.
Express News | Guangzhou Baiyunshan Pharmaceutical - Proposes to Appoint Li Xiaojun as an Executive Director of 9TH Session
Baiyunshan Unit Gets Authorization for Indian Gooseberry Lozenge Production
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
No Data
